Micro-X Strengthens Strategic Position with Placement to Accelerate Medical Imaging Growth
Micro-X Limited (ASX: MX1) has secured Australian dollars six point one eight million through a placement to professional and sophisticated investors, providing funding to accelerate commercial execution across its medical imaging portfolio. Strategic partner Billion Prima committed Australian dollars three million, lifting its shareholding to eight point six percent and reinforcing confidence in Micro-X’s technology and long-term collaboration. Proceeds will be directed toward expanding commercial activity, scaling manufacturing capability, and advancing productisation of the Head CT system ahead of regulatory milestones. The company is targeting multiple near-term catalysts, including larger Rover mobile X-ray sales opportunities, commencement of in-hospital Head CT trials, and further monetisation of security technology partnerships. The placement was completed at minimal discount to recent trading levels, reflecting strong investor support. With growing momentum across healthcare and security markets, the capital raise positions Micro-X to execute on its strategy and support the delivery of high-value products at increased scale.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Micro-X Strengthens Strategic Position with Placement to Accelerate Medical Imaging Growth
Micro-X Limited (ASX: MX1) has secured Australian dollars six point one eight million through a placement to professional and sophisticated investors, providing funding to accelerate commercial execution across its medical imaging portfolio. Strategic partner Billion Prima committed Australian dollars three million, lifting its shareholding to eight point six percent and reinforcing confidence in Micro-X’s technology and long-term collaboration. Proceeds will be directed toward expanding commercial activity, scaling manufacturing capability, and advancing productisation of the Head CT system ahead of regulatory milestones. The company is targeting multiple near-term catalysts, including larger Rover mobile X-ray sales opportunities, commencement of in-hospital Head CT trials, and further monetisation of security technology partnerships. The placement was completed at minimal discount to recent trading levels, reflecting strong investor support. With growing momentum across healthcare and security markets, the capital raise positions Micro-X to execute on its strategy and support the delivery of high-value products at increased scale.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au